Limits...
Antifungal Activity of Brazilian Propolis Microparticles against Yeasts Isolated from Vulvovaginal Candidiasis.

Dota KF, Consolaro ME, Svidzinski TI, Bruschi ML - Evid Based Complement Alternat Med (2011)

Bottom Line: However, all of them were sensitive or dose-dependent susceptible for Amphotericin B.All yeasts were inhibited by PE and PMs, with small variation, independent of the species of yeast.The overall results provided important information for the potential application of PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.

View Article: PubMed Central - PubMed

Affiliation: Graduate Program of Health Sciences, State University of Maringa, Parana, Brazil.

ABSTRACT
Propolis, a resinous compound produced by Apis mellifera L. bees, is known to possess a variety of biological activities and is applied in the therapy of various infectious diseases. The aim of this study was to evaluate the in vitro antifungal activity of propolis ethanol extract (PE) and propolis microparticles (PMs) obtained from a sample of Brazilian propolis against clinical yeast isolates of importance in the vulvovaginal candidiasis (VVC). PE was used to prepare the microparticles. Yeast isolates (n = 89), obtained from vaginal exudates of patients with VVC, were exposed to the PE and the PMs. Moreover, the main antifungal drugs used in the treatment of VVC (Fluconazole, Voriconazole, Itraconazole, Ketoconazole, Miconazole and Amphotericin B) were also tested. Minimum inhibitory concentration (MIC) was determined according to the standard broth microdilution method. Some Candida albicans isolates showed resistance or dose-dependent susceptibility for the azolic drugs and Amphotericin B. Non-C. albicans isolates showed more resistance and dose-dependent susceptibility for the azolic drugs than C. albicans. However, all of them were sensitive or dose-dependent susceptible for Amphotericin B. All yeasts were inhibited by PE and PMs, with small variation, independent of the species of yeast. The overall results provided important information for the potential application of PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.

No MeSH data available.


Related in: MedlinePlus

The hypothetical diagram for comparing the antimicrobial activity of propolis extract and propolis microparticles.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3094883&req=5

fig4: The hypothetical diagram for comparing the antimicrobial activity of propolis extract and propolis microparticles.

Mentions: In relationship to the activity of the antifungal drugs against the tested yeasts, several isolates showed resistance and dose-dependent susceptibility for azolics, and some resistance for AMB. The strains of non-C. albicans showed more resistance and dose-dependent susceptibility than C. albicans. However, all the yeasts, both C. albicans and non-C. albicans, were inhibited by PE and PMs, showing that both are effective. For PMs, a bigger TPC was necessary than the PE, which did not alter the inhibition profile (Figure 3). Similar results were shown when propolis extractive solutions and their respective PMs were tested against oral pathogens [12]. Considering the PE dryness residue, the PE amount added to prepare the microparticles and the drug trapping efficiency of PMs, that was not greater than 78.51 ± 2.81%, the PMs activity was similar to the PE. The hypothetical diagram is presented in Figure 4. Moreover, the results of Oliveira et al. [13] showed a high sensitivity to PE against C. albicans and non-C. albicans isolated from patients with onychomycoses, evidencing an excellent efficacy.


Antifungal Activity of Brazilian Propolis Microparticles against Yeasts Isolated from Vulvovaginal Candidiasis.

Dota KF, Consolaro ME, Svidzinski TI, Bruschi ML - Evid Based Complement Alternat Med (2011)

The hypothetical diagram for comparing the antimicrobial activity of propolis extract and propolis microparticles.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3094883&req=5

fig4: The hypothetical diagram for comparing the antimicrobial activity of propolis extract and propolis microparticles.
Mentions: In relationship to the activity of the antifungal drugs against the tested yeasts, several isolates showed resistance and dose-dependent susceptibility for azolics, and some resistance for AMB. The strains of non-C. albicans showed more resistance and dose-dependent susceptibility than C. albicans. However, all the yeasts, both C. albicans and non-C. albicans, were inhibited by PE and PMs, showing that both are effective. For PMs, a bigger TPC was necessary than the PE, which did not alter the inhibition profile (Figure 3). Similar results were shown when propolis extractive solutions and their respective PMs were tested against oral pathogens [12]. Considering the PE dryness residue, the PE amount added to prepare the microparticles and the drug trapping efficiency of PMs, that was not greater than 78.51 ± 2.81%, the PMs activity was similar to the PE. The hypothetical diagram is presented in Figure 4. Moreover, the results of Oliveira et al. [13] showed a high sensitivity to PE against C. albicans and non-C. albicans isolated from patients with onychomycoses, evidencing an excellent efficacy.

Bottom Line: However, all of them were sensitive or dose-dependent susceptible for Amphotericin B.All yeasts were inhibited by PE and PMs, with small variation, independent of the species of yeast.The overall results provided important information for the potential application of PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.

View Article: PubMed Central - PubMed

Affiliation: Graduate Program of Health Sciences, State University of Maringa, Parana, Brazil.

ABSTRACT
Propolis, a resinous compound produced by Apis mellifera L. bees, is known to possess a variety of biological activities and is applied in the therapy of various infectious diseases. The aim of this study was to evaluate the in vitro antifungal activity of propolis ethanol extract (PE) and propolis microparticles (PMs) obtained from a sample of Brazilian propolis against clinical yeast isolates of importance in the vulvovaginal candidiasis (VVC). PE was used to prepare the microparticles. Yeast isolates (n = 89), obtained from vaginal exudates of patients with VVC, were exposed to the PE and the PMs. Moreover, the main antifungal drugs used in the treatment of VVC (Fluconazole, Voriconazole, Itraconazole, Ketoconazole, Miconazole and Amphotericin B) were also tested. Minimum inhibitory concentration (MIC) was determined according to the standard broth microdilution method. Some Candida albicans isolates showed resistance or dose-dependent susceptibility for the azolic drugs and Amphotericin B. Non-C. albicans isolates showed more resistance and dose-dependent susceptibility for the azolic drugs than C. albicans. However, all of them were sensitive or dose-dependent susceptible for Amphotericin B. All yeasts were inhibited by PE and PMs, with small variation, independent of the species of yeast. The overall results provided important information for the potential application of PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.

No MeSH data available.


Related in: MedlinePlus